Numbers Flashcards
<p>PKU incidence</p>
<p>1:100,000</p>
<p>PKU and risk congenital heart defect</p>
<p>7-10%</p>
<p>Fetal Phe levels </p>
<p>1.25-2.5x more than maternal</p>
<p>Woman >40yo how many pregnancies unplanned?</p>
<p>20%</p>
<p>Percentage of TOP in women >40yo</p>
<p>28%</p>
<p>Background risk VTE in non-pregnant non-contraceptive users</p>
<p>2:10,000</p>
<p>% normal population with anti phospholipid antibodies </p>
<p>1-2%</p>
<p>% of those with recurrent thrombosis with APS</p>
<p>20%</p>
<p>% of those with recurrent miscarriage with APS</p>
<p>15%</p>
<p>Risk of female carrier BRCA 1 developing breast cancer <70</p>
<p>60-80%</p>
<p>Risk of female carrier of BRaC-2 developing breast ca <70</p>
<p>45-85%</p>
<p>Incidence ectopic UK</p>
<p>11:1000</p>
<p>Incidence perforation in OP hysteroscopy</p>
<p>0.002-1.7%</p>
<p>Incidence of perforation in hysteroscopic surgery</p>
<p>1.6%</p>
<p>Perforation in ERPC for PPH</p>
<p>5%</p>
<p>Perforation for PMB Ix</p>
<p>0.2-2%</p>
<p>Perforation in TOP</p>
<p>0.4-0.5%</p>
<p>Cure rate GTD/GTN</p>
<p>98-100%</p>
<p>Incidence GTD</p>
<p>1:714 live births</p>
<p>PCOS in reproductive age</p>
<p>10-18%</p>
<p>Metabolic syndrome in PCOS</p>
<p>33%</p>
<p>Sickle cell heterozygous (trait) in UK</p>
<p>240,000</p>
<p>Sickle cell disease UK</p>
<p>12,500</p>
<p>Lifetime prevalence of uterovaginal prolapse</p>
<p>30-50%</p>
<p>Per cent of women who have had surgery for UV prolapse by 80yo</p>
<p>12%</p>
<p>VBAC success overall</p>
<p>72-75%</p>
<p>VBAC + prev vaginal delivery success</p>
<p>85-90%</p>
<p>Success of VBAC + prev CS for fetal malpresentation </p>
<p>84%</p>
<p>Success of VBAC if prev CS fetal distress</p>
<p>73%</p>
<p>Success of VBAC + prev cs for Labour dystocia</p>
<p>64%</p>
<p>Background risk VTE women in 1 yr</p>
<p>2:10,000</p>
<p>Risk VTE in CHC + ethinlyestradiol + levogernestrel/norgestimate/norethisterone</p>
<p>5-7:10,000</p>
<p>Risk of VTE in etonogestrel (ring) or norelgestromin (patch)</p>
<p>6-12: 10,000</p>
<p>Risk VTE with ethinylestradiol + gestodone/desogestrel/drosperinone</p>
<p>9-12:10,000</p>
<p>Conception rate after UPA (within 120hrs)</p>
<p>1.3%</p>
<p>Conception rate after LNG</p>
<p>2.2%</p>
<p>Women who have gonorrhiea and chlamydia co-infection </p>
<p>40%</p>
<p>UV prolapse lifetime prevalence</p>
<p>30-50%</p>
<p>Vaginal vault prolapse recurrence after uterosacral ligament suspension</p>
<p>5-12%</p>
<p>Recurrence rate of vaginal vault prolapse after sacrocolpopexy</p>
<p>3-5%</p>
<p>Rate of increased UI after VH</p>
<p>60% over 60yo</p>
<p>Dyspareunia after anterior repair</p>
<p>15%</p>
<p>Risks of sacrocolpopexy
- mesh erosion
- SBO
- ileus
- recurrence</p>
<p>10.5%
1.2%
0.3%
3-5%</p>
<p>Per cent of women in lifetime who will have surgery for ovarian mass</p>
<p>10%</p>
<p>Incidence of ovarian cyst in premenopausal being malignant</p>
<p>1:1000</p>
<p>Incidence of ovarian cyst being malignant in 50yo</p>
<p>3:1000</p>
<p>Per cent of TOA being malignant in postmenopausal</p>
<p>49%</p>
<p>Per cent with chronic pelvic pain after 1 episode 2 episodes 3 episodes Of PID/TOA</p>
<p>12%
30%
67%</p>
<p>Per cent of women under 40 affected by POI</p>
<p>1%</p>
<p>Most common cause of premature ovarian insufficiency</p>
<p>Idiopathic 90%
| Chromosomal, AI, infective and iatrogenic 10%</p>
<p>IVF - mild OHSS</p>
<p>33%</p>
<p>IVF - mod/severe OHSS</p>
<p>3-8%</p>
<p>Prevalence of POI</p>
<p>1:100</p>
<p>Main cause of POI</p>
<p>90% idiopathic</p>
<p>Sensitivity of amniocentesis for diagnosing fetal CMV?</p>
<p>60-70%</p>
<p>Percentage of clinically significant red cell autoantibodies in pregnancy</p>
<p>0.4%</p>
<p>Percentage of red cell autoantibodies in pregnancy</p>
<p>1.2%</p>
<p>Level of anti K to refer to fetal med</p>
<p>any</p>
<p>Level of anti D to refer to fetal med</p>
<p>>4</p>
<p>Level of anti C to refer to fetal med</p>
<p>>7.5</p>
<p>Level of anti E to refer to fetal med</p>
<p>When anti C detected</p>
<p>Aim of transfusion PCV for fetal anaemia</p>
<p>PCV 0.7-0.85</p>
<p>Aim of transfusion PCV for neonatal anaemia </p>
<p>PCV 0.5-0.6</p>
<p>Percentage of women with bipolar disorder, without family history, of developing postpartum pyschosis</p>
<p>1:4</p>
<p>Percentage of women with bipolar disorder, with family history, of developing postpartum pyschosis</p>
<p>1:2</p>
<p>Risk of congenital infection with recurrent CMV</p>
<p>1-2%</p>
<p>Risk of congenital infection with primary CMV</p>
<p>30-40%</p>
<p>What percentage of infants with congenital CMV infection are symptomatic?</p>
<p>10-15%</p>
<p>Maternal mortality in UK?</p>
<p>8.76 per 100,000</p>
<p>Percentage of twins in live births?</p>
<p>3%</p>
<p>Incidence of puerperal genital haematoma?
| Requiring surgical intervention?</p>
<p>1:700
| 1:1000</p>
<p>Congenital malformations of women with epilepsy without AEDs</p>
<p>2.8%</p>
<p>Valproate and congenital malformations</p>
<p>10.7%</p>
<p>AED Polytherapy and congenital malformations</p>
<p>16%</p>
<p>Risk of congenital malformations if previously affected child </p>
<p>16.8%</p>
<p>Lamotrigine and congenital malformations</p>
<p>2%</p>
<p>Carbamazepine and congenital malformations</p>
<p>3.4%</p>
<p>Keppra and congenital malformations</p>
<p>0.7%</p>
<p>Phenobarbital and congenital malformations</p>
<p>4.9%</p>
<p>Phenytoin and congenital malformations</p>
<p>7.36%</p>
<p>Risk of seizure in labour with epilepsy</p>
<p>1-4%</p>
<p>Percentage of brachial plexus injury in shoulder dystocia</p>
<p>2.3-16%</p>
<p>Maximum dose of lidocaine + adrenaline</p>
<p>7ml/kg</p>
<p>Risk of future PIH if previous PIH</p>
<p>16-47%</p>
<p>Risk of PET if previous PIH</p>
<p>2-7%</p>
<p>Risk of PIH if previous PET</p>
<p>13-53%</p>
<p>Risk of PET if previous PET</p>
<p>16%</p>
<p>Risk of PET if previous severe PET/HELLP/eclampsia led to birth <34/40</p>
<p>25%</p>
<p>Risk of PET if previous eclampsia led to birth <28/40</p>
<p>55%</p>
<p>Risk RDS at 37/40 ELCS</p>
<p>11%</p>
<p>Risk RDS at 38/40 ELCS</p>
<p>8%</p>
<p>Risk RDS at 39/40 ELCS</p>
<p>1.5%</p>
<p>Steroids reduce RDS by what per cent?</p>
<p>44%</p>
<p>Risk of miscarriage with amniocentesis</p>
<p>0.11%</p>
<p>Risk of miscarriage with CVS</p>
<p>0.22%</p>
<p>Percentage of inconclusive cffDNA tests</p>
<p>1.9-6%</p>
<p>cffDNA sensitivity and specificity for T21</p>
<p>99.4%, 99.9%</p>
<p>cffDNA sensitivity and specificity for T18</p>
<p>97.7%, 99.9%</p>
<p>Female tubal sterilisation failure rate</p>
<p>0.85-1.85%</p>
<p>Incidence of adnexal masses in pregnancy
The incidence of ovarian malignancy in pregnancy
</p>
<p>0.19–8.8%
| 1 in 1500–32 000 pregnancies</p>
<p>Hyperreactio luteinalis - percentage of maternal virilisation?</p>
<p>14-25%</p>
<p>Luteoma of pregnancy - percentage of maternal virilisation?</p>
<p>25-50%
| 50% of these have risk of fetal virilisation if female</p>
<p>Risk of heterotopic pregnancy in assisted reproduction?</p>
<p>1-2%</p>
<p>Risk of torsion of >6cm dermoid cyst in pregnancy</p>
<p>27%</p>
<p>Percentage that malignant germ cell tumours account for in ovarian tumours in pregnancy?</p>
<p>38%</p>
<p>Prevalence of acute appendicitis in pregnancy?</p>
<p>1:1500</p>
<p>Percentage of adnexal masses that are simple ovarian cysts <5cm in pregnancy</p>
<p>76%</p>
<p>Incidence of ovarian torsion in pregnancy</p>
<p>1-5:1000</p>
<p>Risk of mid trimester losses after radical trachelectomy</p>
<p>7% vs 4% BG</p>
<p>Risk of preterm births after trachelectomy</p>
<p>30%</p>
<p>LBR after trachelectomy</p>
<p>62.8%</p>
<p>Peripartum seizure risk in epilepsy</p>
<p>1-4%</p>
<p>Percentage of women with vasomotor symptoms after menopause</p>
<p>70%</p>
<p>Risk additional breast cancer cases if using HRT (E+P) for 5 years</p>
<p>6 extra per 1000
| (BG 22-48:1000 over 7.5yrs)</p>
<p>Risk of radiation cystitis</p>
<p>26%</p>
<p>Risk of bowel fistulae after radiotherapy for cervical ca.</p>
<p>8%</p>
<p>Risk of bladder atony requiring ISC after radical hysterectomy</p>
<p>2-3%</p>
<p>Risk of bowel obstruction after radiotherapy for cervical cancer</p>
<p>14.5%</p>
<p>Dyspareunia post radiotherapy for cervical cancer</p>
<p>55%</p>
<p>Recurrence of abruption after 1 previous</p>
<p>4%</p>
<p>Recurrence after 2 previous abruptions</p>
<p>19-25%</p>
<p>Risk of malignant potential in lichen sclerosis</p>
<p>5%</p>
<p>Risk of malignant potential in lichen planus</p>
<p>3%</p>
<p>5yr survival of Stage 1 cervical ca</p>
<p>80%</p>
<p>5yr survival of Stage 2 cervical ca</p>
<p>50%</p>
<p>5yr survival of Stage 3 cervical ca</p>
<p>20%</p>
<p>5yr survival of Stage 2 cervical ca</p>
<p>7%</p>
<p>Percentage of bilateral dysgerminomas</p>
<p>10%</p>
<p>Percentage of raised CA125 in EOC</p>
<p>>80%</p>
<p>Percentage of HMB due to submucosal fibroids</p>
<p>15%</p>
<p>Pregnancy post endometrial ablation</p>
<p>0.7%</p>
<p>Percentage of reoperation after endometrial ablation</p>
<p>20-27%</p>
<p>Percentage of women having hysterectomy in 5 years after endometrial ablation</p>
<p>14-20%</p>
<p>Percentage of women with cyclical bleeding post subtotal hysterectomy</p>
<p>5%</p>
<p>Percentage of PCO in general population</p>
<p>20-33%</p>
<p>Percentage of anovulatory infertility due to PCOS</p>
<p>80-90%</p>
<p>Percentage of ovulation induction with clomiphene citrate</p>
<p>70-85%</p>
<p>Percentage of patients pregnant after 6 cycles of clomiphene citrate</p>
<p>60-70%</p>
<p>Risk of multiple pregnancy in clomiphene citrate ovulation induction</p>
<p>10%</p>
<p>Risk of multiple pregnancy in gonadotrophin ovulation induction</p>
<p><5</p>
<p>Percentage of endometriosis in reproductive age</p>
<p>6-10%</p>
<p>Sensitivity and specificity of dyschezia and deep dyspareunia for deep infiltrating endometriosis</p>
<p>74.5%
| 68.7%</p>
<p>Risk of premature ovarian failure in bilateral endometrioma cystectomies</p>
<p>2.4%</p>
<p>Lifetime risk of colon cancer in Lynch syndrome</p>
<p>50-80%</p>
<p>Lifetime risk of endometrial cancer in Lynch syndrome</p>
<p>40-60%</p>
<p>Lifetime risk of ovarian cancer in Lynch syndrome</p>
<p>10-12%</p>
<p>Risk of primary peritoneal malignancy in BRCA1/ BRCA2 with oophorectomy</p>
<p>1-6%</p>
<p>5yr survival for ovarian cancer Stage 1</p>
<p>92%</p>
<p>5yr survival for ovarian cancer Stage 2</p>
<p>55%</p>
<p>5yr survival for ovarian cancer Stage 3</p>
<p>22%</p>
<p>5yr survival for ovarian cancer Stage 4</p>
<p>6%</p>
<p>5yr survival for ovarian cancer overall</p>
<p>43%</p>
<p>5yr survival for endometrial cancer Stage 1</p>
<p>95%</p>
<p>5yr survival for endometrial cancer Stage 2</p>
<p>77%</p>
<p>5yr survival for endometrial cancer Stage 3</p>
<p>39%</p>
<p>5yr survival for endometrial cancer Stage 4</p>
<p>14%</p>
<p>5yr survival for endometrial cancer overall</p>
<p>84.4%</p>
<p>Prevalence of cerebral palsy in <28/40</p>
<p>110:1000
| 1:10</p>
<p>Prevalence of cerebral palsy between 28-31/40</p>
<p>43:1000</p>
<p>Prevalence of cerebral palsy between 32-36/40</p>
<p>6.75:1000</p>
<p>Prevalence of cerebral palsy in >36/40</p>
<p>1.35:1000</p>
<p>Percentage of cerebral palsy due to PTB</p>
<p>35%</p>
<p>Percentage of pregnant women with anaemia</p>
<p>38%</p>
<p>Percentage of women with HMB and iron deficiency anaemia
| or with severe iron deficiency</p>
<p>27%
| 60%</p>
<p>Percentage that an ectopic pregnancy with 1 previous CS is a scar pregnancy</p>
<p>6.1%</p>
<p>Risk of recurrence of CS scar</p>
<p>3.25-5%</p>
<p>5 year survival in recurrent cervical cancer</p>
<p>6-77%</p>
<p>Pelvic exenteration mortality rate</p>
<p>Up to 14%</p>
<p>Pelvic exenteration morbidity rate</p>
<p>33-75%
| Serious 50%</p>
<p>5 year survival after pelvic exenteration</p>
<p>54%
87% of these survive 10yrs+
Higher success if >5yr disease free interval, R0 and no lymph node involvement</p>
<p>Risk of recurrent pregnancy loss in prothrombin gene mutation</p>
<p>81%</p>
<p>Percentage of maternal deaths with recognised mental health problem</p>
<p>16.8%</p>
<p>Risk to baby with homebirth in nullips</p>
<p>4:1000</p>
<p>Percentage of transfer of nullips from home to obs unit</p>
<p>45%</p>
<p>Percentage of bowel injuries diagnosed post diagnostic laparoscopy</p>
<p>15%</p>
<p>Percentage of bladder injuries diagnosed post diagnostic laparoscopy</p>
<p>50%</p>
<p>Percentage of ureteric injuries diagnosed post diagnostic laparoscopy</p>
<p>70%</p>
<p>Failure rate of lap. sterilisation</p>
<p>1:200</p>
<p>Rate of adhesion at umbilicus after midline laparotomy</p>
<p>50%</p>
<p>Rate of adhesion at umbilicus after low transverse incision</p>
<p>23%</p>
<p>TOG - rate of bladder injuries in laparoscopy</p>
<p>0.02-8.3%</p>
<p>% of fistula formation in laparoscopic bladder injury</p>
<p>5%</p>
<p>% laparoscopic ureteric injury
% in LAVH
% in DIE</p>
<p>1-2%
9-11%
38%</p>
<p>Laparoscopic ureteric injury
- lower 1/3
- middle 1/3
- upper 1/3</p>
<p>50%
30%
18%</p>
<p>% unrecognised ureteric injuries resulting in a nephrectomy</p>
<p>25%</p>
<p>% of neuro morbidity in DCDA if 1 twin death?</p>
<p>1%</p>
<p>% of neuro morbidity in MCDA if 1 twin death</p>
<p>26%</p>
<p>% of death in DCDA if 1 twin death</p>
<p>4%</p>
<p>% of death in MCDA if 1 twin death</p>
<p>15%</p>
<p>% of laparotomy conversion for laparoscopic hysterectomy</p>
<p>0.83-7%
0. 83% for subtotal
2. 79% for total</p>
<p>% with adhesions after open gynae surgery</p>
<p>34.5%</p>
<p>TOG: % of perforations by fitting an IUD
| % of these resulting in bowel injury</p>
<p>15%
| 3-7%</p>
<p>Rate of hysterectomy following perforation from TOP</p>
<p>7:100,000</p>
<p>% uterine perforations affecting anterior wall</p>
<p>40%</p>
<p>% uterine perforations affecting cervix</p>
<p>36%</p>
<p>% uterine perforations affecting right lateral wall</p>
<p>21%</p>
<p>% uterine perforations by suction curette</p>
<p>51%</p>
<p>% uterine perforations by Hegar</p>
<p>24%</p>
<p>% uterine perforations by curette</p>
<p>16%</p>
TVS sensitivity and specificity for Dx ectopic
87-99% sensitivity
94-99.9% specificity
% of pseudosacs within uterine cavity in ectopic pregnancies
20%
Incidence of CS scar pregnancies
1:2000
% of interstitial in ectopic pregnancies
1-6.3%
Incidence of cornual ectopics
1:67,000
Ongoing pregnancy rate in salpingotomy
Repeat ectopics
60.7%
8%
Ongoing pregnancy rate in salpingectomy
Repeat ectopics
56.2%
5%
Rate of women needing further surgery after salpingotomy?
1:5
Success rate of 1st dose of methotrexate in ectopic Mx
65-95%
% needing 2nd dose of methotrexate for ectopic Mx
3-27% greentop
14% PassMRCOG
Success rate of expectant Mx ectopics if HCG <1000
80-90%
Success rate of expectant Mx ectopics if HCG <2000
60-67%
% of recurrent ectopics
18.5%
% of 2nd trimester miscarriages
1-2%
% miscarriages 12-19yo
13%
% miscarriages 20-24yo
11%
% miscarriages in 25-29yo
12%
% miscarriages in 30-34yo
15%
% miscarriages in 35-39yo
25%
% miscarriages in 40-44yo
51%
% miscarriages in >45yo
93%
% who miscarry after 3 consecutive miscarriages
40%
% women with recurrent miscarriages and congenital uterine malformations
1.8-37.6%
% women needing chemotherapy with complete molar pregnancy
15%
% women needing chemotherapy with partial molar pregnancy
0.5%
GTN incidence
1:50,000 after live birth
Incidence GTD
1:714 live births
GTN cure rate
98-100%
% LBR in twin pregnancy with co-existent molar
25%
% miscarriage in twin pregnancy with co-existent molar
40%
% PTB in twin pregnancy with co-existent molar
36%
GTN cure rate FIGO <6
almost 100%
GTN cure rate FIGO >7
almost 95%
% hyperemesis gravidarum
0.3-3.6%
Hyperemesis gravidarum recurrence
15.2-81%
% pregnancy loss in Wernicke’s encephalopathy
48%
% women with OHSS managed as inpatients
0.3%
% of cerebral palsy in 22-27/40
14.6%
% of cerebral palsy in 28-31/40
6.2%
% of cerebral palsy in 32-36/40
0.7%
% of cerebral palsy in term
0.1%
% fetal loss in simple appendicitis
1.5%
% fetal loss in appendicitis with peritonitis
6%
% fetal loss with perforated appendix
36%
